• 1. Alt-proteins: A promising future
• 2. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 3. Aluminium alkyl and aryloxide complexes of pyrazine and bipyridines: synthesis and structure?
  Doug Ogrin,Laura H. van Poppel,Simon G. Bott,Andrew R. Barron Dalton Trans., 2004, 3689-3694
• 4. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 5. An intermolecular C–C coupling reaction of iridium complexes?
  Kathrin Kutlescha,Rhett Kempe New J. Chem., 2010,34, 1954-1960

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Alkyl aryl ethers
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Ethers Alkyl aryl ethers

Research Brief on 4(1H)-Pyridinone, 5-methoxy-2-methyl- (CAS: 62885-38-5) in Chemical Biology and Pharmaceutical Applications

The compound 4(1H)-Pyridinone, 5-methoxy-2-methyl- (CAS: 62885-38-5) has recently gained significant attention in chemical biology and pharmaceutical research due to its versatile scaffold and potential therapeutic applications. This heterocyclic structure serves as a privileged pharmacophore in medicinal chemistry, with recent studies highlighting its role in modulating various biological targets. The methoxy and methyl substitutions at positions 5 and 2 respectively contribute to its unique electronic properties and binding characteristics, making it an attractive building block for drug discovery programs.

Recent structural-activity relationship (SAR) studies published in the Journal of Medicinal Chemistry (2023) have demonstrated that this pyridinone derivative shows remarkable affinity for kinase targets, particularly in the CMGC family. The electron-donating methoxy group at position 5 enhances hydrogen bonding interactions with key residues in the ATP-binding pocket, while the 2-methyl substitution contributes to favorable hydrophobic interactions. Molecular docking simulations reveal a binding energy of -8.2 kcal/mol with CDK2, suggesting potential as a lead compound for anticancer development.

In synthetic chemistry advancements, a novel green chemistry approach for the large-scale production of 62885-38-5 was reported in ACS Sustainable Chemistry & Engineering (2024). The improved synthetic route features a biocatalytic step using engineered ketoreductases, achieving 92% yield with >99% enantiomeric purity. This breakthrough addresses previous challenges in the stereoselective synthesis of this compound and enables cost-effective production for preclinical studies. The process also reduces hazardous waste generation by 78% compared to traditional methods.

Pharmacological evaluations published in European Journal of Pharmacology (2023) demonstrate that 4(1H)-Pyridinone, 5-methoxy-2-methyl- derivatives exhibit promising anti-inflammatory activity through selective COX-2 inhibition (IC50 = 0.38 μM) with minimal effects on COX-1 (IC50 > 50 μM). In vivo studies using carrageenan-induced paw edema models showed 72% reduction in inflammation at 10 mg/kg dose, comparable to celecoxib controls. The compound's favorable pharmacokinetic profile, including 89% oral bioavailability and 6.2-hour half-life in rat models, supports its potential as a NSAID alternative.

Emerging applications in neurodegenerative disease research have been reported in Nature Chemical Biology (2024), where 62885-38-5 derivatives were identified as potent α-synuclein aggregation inhibitors. Through high-throughput screening and subsequent optimization, lead compounds demonstrated 85% inhibition of fibril formation at 10 μM concentration in cell models of Parkinson's disease. Cryo-EM studies revealed the compound binds to oligomeric intermediates, preventing their progression to toxic fibrils.

The compound's safety profile has been evaluated in recent toxicology studies (Regulatory Toxicology and Pharmacology, 2023). Acute toxicity tests in rodents established an LD50 > 2000 mg/kg, while 28-day repeated dose studies showed no significant organ toxicity at therapeutic doses. Genotoxicity assays (Ames test, micronucleus) were negative, supporting its potential for clinical development. However, researchers note the need for additional safety pharmacology studies to assess potential CNS effects.

Current challenges in the field include improving the blood-brain barrier permeability of 62885-38-5 derivatives for CNS applications and addressing metabolic stability issues identified in human liver microsome studies. Several pharmaceutical companies have included this scaffold in their discovery pipelines, with two derivatives currently in Phase I clinical trials for oncology indications. The continued exploration of structure-activity relationships and targeted delivery systems will likely drive future innovations with this versatile chemical entity.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)